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ABSTRACT
Background Despite vitamin K antagonists (VKA) being 
the gold standard in the prevention of thromboembolic 
events in antiphospholipid syndrome (APS), non- vitamin K 
antagonists oral anticoagulants/direct oral anticoagulants 
(DOACs) have been used off- label.
Objective We aimed to perform a systematic review 
comparing DOACs to VKA regarding prevention of 
thromboembolic events, occurrence of bleeding events and 
mortality in patients with APS.
Methods An electronic database search was performed 
through MEDLINE, CENTRAL and Web of Science. After 
data extraction, we pooled the results using risk ratio (RR) 
and 95% CI. Heterogeneity was assessed using the I². The 
outcomes considered were all thromboembolic events 
as primary, and major bleeding, all bleeding events and 
mortality as secondary. Evidence confidence was assessed 
using the Grading of Recommendations Assessment, 
Development and Evaluation methodology.
Results We included 7 studies and a total of 835 
patients for analyses. Thromboembolic events were 
significantly increased in DOACs arm, compared with 
VKA—RR 1.69, 95% CI 1.09 to 2.62, I²—24%, n=719, 6 
studies. In studies using exclusively rivaroxaban, which 
was the most representative drug in all included studies, 
the thromboembolic risk was increased threefold (RR 
3.36, 95% CI 1.53 to 7.37). The risks of major bleeding, 
all bleeding events and mortality were not significantly 
different from control arm. The grade of certainty of our 
results is very low.
Conclusions Current evidence suggests DOACs use, 
particularly rivaroxaban, among patients with APS, is 
less effective than VKA since it is associated with 69% 
increased risk of thromboembolic events.
Trial registration number CRD42020216178.
INTRODUCTION
Antiphospholipid syndrome (APS) is an 
acquired autoimmune disease defined by 
the association of thromboembolic events 
(venous, arterial or microvascular) and/
or pregnancy morbidity and the persistent 
presence of antiphospholipid (aPL) anti-
bodies, such as lupus anticoagulant, anticar-
diolipin and anti-β2- glycoprotein 1.1 2 Triple- 
positive patients, who show a worse prognosis, 
represent less than 50% of those positive for 
one or two tests.3 A previous systematic review 
suggests that aPL antibodies were detected 
in 6% of women with pregnancy morbidity, 
in 13.5% of patients with stroke/transient 
ischaemic attack (TIA), 11% with myocar-
dial infarction (MI) and 9.5% with deep 
vein thrombosis.4 Therefore, being throm-
boembolic diseases of major concern due to 
their high prevalence and often fatal conse-
quences,5 the diagnosis and prognosis of APS 
should not be underestimated and treated 
accordingly.
Vitamin K antagonists (VKA) have been the 
gold standard in the primary and secondary 
prevention of thromboembolic events in APS. 
Key messages
What is already known about this subject?
 ► Direct oral anticoagulants (DOACs) have been used 
off- label in the primary and secondary preven-
tion of thromboembolic events in antiphospholipid 
syndrome.
What does this study add?
 ► This systematic review and meta- analysis shows 
that DOACs increase the relative risk of thromboem-
bolic events, major bleeding events and mortality in 
these patients, compared with vitamin K antagonists.
How might this impact on clinical practice or 
further developments?
 ► Current evidence does not support the use of DOACs, 
particularly rivaroxaban, in antiphospholipid syn-
drome. Thus, vitamin K antagonists should remain 
as gold standard in these patients.
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The target international normalised ratios (INR) interval 
should be between 2.0 and 3.0, but long- term treatment 
is a great medical challenge in these patients, particularly 
due to the risk of major bleeding.6 7
Another class of anticoagulants, the non- vitamin K 
antagonists oral anticoagulants (NOACs), also called 
direct oral anticoagulants (DOACs), have been used in 
many countries worldwide in the treatment and preven-
tion of venous thromboembolism (VTE) as well as in 
stroke prevention in atrial fibrillation. DOACs include 
drugs such as apixaban, edoxaban, dabigatran and rivar-
oxaban.8 DOACs revealed several advantages over VKA: 
lower incidence of major bleeding, minor drug and food 
interactions, rapid onset (and also offset) of action, more 
predictable pharmacokinetics and pharmacodynamics 
and lack of need for laboratory monitoring with higher 
patients’ satisfaction.8–10
On the other hand, the data and the experience in this 
area are limited and heterogeneous increasing the uncer-
tainty about the use of DOACs in APS.
Therefore, we aimed to perform a systematic review to 
compare DOACs to VKA regarding prevention of throm-
boembolic events, occurrence of bleeding events and 
mortality in patients with APS.
METHODS
This systematic review followed the principles of MOOSE 
and PRISMA11 12 and was registered in PROSPERO: 
CRD42020216178.
Eligibility criteria
We considered published longitudinal studies 
(randomised controlled trials (RCTs) and observational 
studies, whether retrospective or prospective) comparing 
DOACs with VKA control group in adult patients diag-
nosed with APS. The type of APS (primary vs secondary), 
previously registered thromboembolic events (venous, 
arterial or microvascular) or the aPL antibodies profile 
were not initially relevant for the eligibility criteria. The 
outcomes considered were all thromboembolic events 
as primary, and major bleeding, all bleeding events and 
mortality as secondary. As rule, our all bleeding events 
encompass any type of bleeding, either major, clinically 
relevant non- major or minor.
Reviews, case series, case reports, commentaries or 
studies with unclear outcomes were not included.
Information sources and search strategies
An electronic database search for relevant material 
for inclusion criteria through MEDLINE, CENTRAL 
Figure 1 Study flow chart.
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(Cochrane Central Register of Controlled Trials) and 
Web of Science was performed in March 2020. There 
were no restrictions on language or publication date.
The search strategy is detailed in online supplemental 
data 1.
Studies records and data extraction
Two reviewers (NK and MA) screened the titles and 
abstracts yielded by the searches against the inclusion 
criteria and then read the full text reports and deter-
mined whether they met the inclusion criteria or not, 
the discrepancies being resolved by consensus. Reasons 
for the exclusion of articles were recorded at the full text 
screening stage. The data from included studies were 
uploaded onto a prepilot form, which included informa-
tion such as study type, interventions, inclusion criteria, 
follow- up time, population main characteristics and 
outcomes. When studies presented different estimates, 
we used the most precise or adjusted measure.
Risk of bias
Each study was evaluated independently by two authors 
(NK and MA) in each of the domains of bias contained 
in the tools. For RCTs, we used the Cochrane risk of 
bias tool (RoB 2.0 tool)13 and for observational studies, 
the ROBINS- I tool,14 where all domains were classified 
accordingly to the algorithm. Then, the overall risk of bias 
judgement was performed. In RCTs, the final decision 
was one of: low risk, some concerns or high risk, while 
in observational studies it was one of: low risk, moderate 
risk, serious risk, critical risk or no information.
In case of posthoc analyses, while using data from the 
study, we additionally approached each one of the orig-
inal trials, to access the risks of bias separately.
Data synthesis
The data was pooled using RevMan V.5.3 (The Nordic 
Cochrane Centre, Copenhagen; The Cochrane Collabo-
ration, 2014).15
In accessing results, the intention- to- treat analysis was 
used, always favouring the bigger denominator.
The outcomes were treated as a dichotomous data and 
risk ratio (RR) and 95% CI were used to estimate pooled 
results from studies.15
Heterogeneity was assessed using the I2.16 The I2 statis-
tics measures the percentage of total variation between 
studies attributed to interstudy heterogeneity rather 
than random. Statistical heterogeneity was considered 
substantial if I2 >50%. Fixed effects model was used by 
default because we wanted to estimate the mean effect 
of NOACs/DOACs in patients with APS. DerSimonian 
and Laird random effects model was only used if I2 > 
50%.15 17 18
Publication bias assessment was performed through 
funnel plot examination if more than 10 studies were 
included.19
Subgroup analyses were done for type of study (RCT 
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(defined according to Sapporo criteria),1 triple- positive 
patients (<60% or≥60%) and type of DOACs used (just 
rivaroxaban vs other DOACs±rivaroxaban).
Assessment of confidence in cumulative evidence
As recommended by the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
Working Group methodology, two reviewers inde-
pendently (NK and MA) assessed all the critical outcomes 
in the following domains: risk of bias, inconsistency, 
indirectness, imprecision and publication bias.20 21 The 
confidence on the pooled evidence was graded as very 
low, low, moderate or high. The pooled relative risks, as 
well as absolute risk measures, and the confidence on the 




The search showed 357 uploaded references and after 
removing all duplicates, 321 remained. Then, 305 were 
excluded for one of the following reasons: background 
article, wrong study design (the model designed for these 
studies did not meet our inclusion criteria), wrong drug, 
wrong population, wrong outcome, duplicate; and just 16 
full- text articles were assessed for eligibility, 6 of which 
had a wrong study design, 2 were protocols of ongoing 
trials and 1 was a commentary to Pengo et al22 (figure 1).
More detailed late stage/full text exclusion criteria are 
available in online supplemental data 2.
Finally, seven studies published between 2016 and 2019 
were included in quantitative synthesis: three open- label 
RCTs;22–24 one posthoc APS subgroup analysis (Gold-
haber et al25 of three RCTs (RE- COVER,26 RE- COVER 
II27 and RE- MEDY28 trials)) evaluating dabigatran in 
the treatment and prevention of VTE and three cohort 
studies (two prospective29 30 and one retrospective).31
Overall, this review included 835 patients with APS—
not all studies were clear about using or not the revised 
Sapporo criteria1 in diagnosing APS—, followed for a 
period range between 210 days and 60 months. Out 
of these, 395 constituted the intervention arm (64.3% 
women) and 440 the control arm (64.3% women). The 
mean age was similar in both groups, 44.0–47.8 years 
range for DOACs and 42.6–51.0 years range for VKA. The 
study by Martinelli et al29 was not included, since authors 
only present patients’ age at first thromboembolic event.
Regarding DOACs, 265 patients were taking rivarox-
aban, 75 dabigatran, 43 apixaban and 12 Edoxaban.
Most trials had warfarin as control, with exception 
of Ordi- Ros et al24 and Malec et al30 trials, which do not 
specify the VKA used.
All studies provided data for the primary and/or 
secondary outcomes of this review22–25 29–31 but only those 
with at least one event in each arm contributed for the 
meta- analysis.
Overall, there were 74 TE events (primary outcome) 
in the included trials, corresponding 55% to arterial 
and 45% to venous thrombosis. Out of 43 registered 
events in DOACs arm, 28 (65%) were arterial, largely 
driven by MI and stroke/TIA, 7 and 20 events, respec-
tively (online supplemental data 3). In VKA arm, despite 
venous predominance, 13 (42%) in 31 events were arte-
rial, out of which 1 corresponded to MI and 8 to stroke/
TIA (online supplemental data 3).
More detailed characteristics of the included studies 
can be seen in table 1.
Risk of bias
Regarding all the outcomes, three studies22–24 were classi-
fied as having some concerns and four25 29–31 at serious/
high risk of bias (tables 2 and 3).
Three RCTs22–24 offer some bias concerns due to devi-
ation from intended intervention. Even though these 
trials were overseen by independent committees or 
had blinded end point adjudication, they were open 
label to ensure optimum drug dosing, monitoring and 
management.
The study by Goldhaber et al25 presents high risk due to 
selective reporting bias, since it was a posthoc analysis of 
three RCTs and there is no previously registered protocol 
available.
The study by Martinelli et al29 has serious risk of bias due 
to confounding—patients’ aPL profile was not appropri-
ately controlled for.
The study by Malec et al30 has serious risk of bias due 
to confounding (risk factors as arterial hypertension, 
dyslipidaemia and triple APS positivity were not adjusted 
among arms), selection of participants (for the interven-
tion arm authors only comprised patients who preferred 
a NOAC/DOAC or had unstable anticoagulation with 
VKAs, defined as time to therapeutic range below 50% 
within the previous 6 months, not being clear about the 
remaining patients), missing data (duration of follow- up 
differed between arms—mean 45 months vs 62 months) 
and measurement of the outcomes (TE events, major 
bleeding and all bleeding events outcomes were assessed 
by clinicians aware of the intervention received by study 
participants).
In addition, the study by Sato et al31 has serious risk 
of bias in the classification of interventions (drug 
regimen—dosage, rout of administration, frequency—is 
not well defined), measurement of outcomes and selec-
tion of reported results. Being a retrospective cohort, 




Thromboembolic events were significantly increased 
in the DOACs arm, compared with the VKA arm—RR 
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Secondary: major bleeding, all bleeding events and mortality
DOACs did not significantly increase the risk of major 
bleeding or mortality with RR 1.22 (95% CI 0.72 to 2.07; 
I²=0%; n=691; five studies) and RR 1.17 (95% CI 0.48 to 
2.84; I²=0%; n=577; four studies), respectively (figure 2.
On the other hand, all bleeding events risk was non- 
significantly decreased in DOACs arm with RR 0.79 (95% 
CI 0.47 to 1.32; I²=66%; n=457; three studies) (figure 2).
Subgroup analysis
Although there was no statistical difference comparing 
RCTs to cohort studies, the magnitude of the increased 
risk of TE in the DOACs arm was superior in RCTs—RR 
2.32, 95% CI 1.14 to 4.72; I²=49%; three studies (online 
supplemental data 4).
Regarding the certainty of APS diagnosis, there were 
no differences among the studies which mention the 
Sapporo criteria and the ones that do not (online supple-
mental data 4).
Studies including at least 60% of triple- positive patients 
presented higher risk of all bleeding events, compared 
with studies with <60% of triple positives, even though 
without achieving significant subgroup difference (RR 
1.19 95% CI 0.77 to 1.85 vs RR 0.61 95% CI 0.41 to 0.90; 
p=0.03) (online supplemental data 4). There were no 
differences regarding other outcomes.
The exclusive use of rivaroxaban presented a statisti-
cally significant increased magnitude of effect regarding 
TE events (RR 3.36, 95% CI 1.53 to 7.37 vs RR 1.08, 
Table 2 Risk of bias assessment (RCTs)—TE events, major bleeding, all bleeding events and mortality
Risk of bias 
arising from the 
randomisation 
process
Risk of bias due to 
deviations from the 
intended interventions 
(effect of assignment 
to intervention and/or 
adhering to intervention)
Risk of bias 
due to missing 
outcome data
Risk of bias in 
measurement 
of the outcome
Risk of bias 
in selection of 
the reported 
result




Low risk Low risk Low risk Low risk Low risk Low risk
Schulman et al
(RE- COVER II)27
Low risk Low risk Low risk Low risk Low risk Low risk
Schulman et al
(RE- MEDY)28
Low risk Low risk Low risk Low risk Low risk Low risk
Goldhaber et al25 Low risk Low risk Low risk Low risk High risk High risk




Low risk Some 
concerns
Pengo et al22 Low risk Some concerns Low risk Low risk Low risk Some 
concerns
Ordi- Ros et al24 Low risk Some concerns Low risk Low risk Low risk Some 
concerns
RCT, randomised controlled trial; TE, thromboembolism.
Table 3 Risk of bias assessment (observational studies)—TE events, major bleeding, all bleeding events and mortality
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95% CI 0.62 to 1.87; p=0.02) (online supplemental data 
4).
Assessment of confidence in cumulative evidence
GRADE
Concerning TE events, the GRADE confidence is very 
low, being downgraded due to study design, risk of bias 
and imprecision (table 4). As for secondary outcomes, 
the GRADE confidence is also very low for the same 
reasons—except for all bleeding events, additionally 
downgraded due to indirectness (table 4).
Since we are combining RCTs with observational 
studies, the overall quality of evidence was assessed using 
the lowest quality of all included studies.
Separated GRADE analysis for RCTs and observational 
studies is available in online supplemental data 5. Consid-
ering only RCTs the GRADE is low, except for all bleeding 
events, which is very low.
DISCUSSION
Our systematic review showed that the use of DOACs, 
compared with VKA, increased the relative risk of 
thromboembolic events by 69% in APS. In the DOACs 
arm, most of the events were arterial (MI and stroke/
TIA)—65%, suggesting that patients with APS with 
history of arterial thrombosis or with other risk factors 
for arterial thrombosis may not be good candidates 
Figure 2 Forest plot of the pooled analysis comparing DOACs vs VKA regarding TE events, major bleeding, all bleeding 
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for DOACs, in particular for rivaroxaban. The anal-
yses including studies with more robust methodology, 
namely RCTs and studies with high APS diagnostic 
certainty, presented an even higher risk of TE events 
in DOACs arm with RR 2.42 and RR 3.18, respectively. 
Additionally, in studies using exclusively rivaroxaban, 
which was the most representative drug in all included 
studies, the thromboembolic risk triples, when 
compared with VKA.
The risk of major bleeding or mortality was increased 
without achieving statistical significance. All bleeding 
events risk was non- significantly decreased in the DOACs 
arm. However, studies with higher risk patients (≥60% 
triple positive) showed quite the opposite. Despite non- 
significant results, this outcome increased substantially 
the risk comparing to VKA, and this probably is related 
to the worse thromboembolic and haemorrhagic 
profile of the included patients.3 Also, it is important to 
refer that in our population, a large portion of relevant 
bleeding events among female patients on rivaroxaban 
were heavy menstrual bleedings, being congruous with 
already existing data.32 33
Therefore, the results of this systematic review give 
scientific support to current recommendations for not 
recommending DOACs for secondary prevention of 
TE in patients with APS, VKA being the elected drug 
class in this context.6 7 Nevertheless, future data from 
observational studies and RCT will be important to 
clarify this risk/benefit in selected group of patients 
and different DOACs. For instance, ASTRO- APS trial 
with apixaban 5 mg two times a day compared with 
warfarin in patients with APS with VTE might change 
our present approach to this class of drugs.
In contrast to atrial fibrillation treatment, where VKA 
demonstrated to be less efficacious and safe,9 34 the 
reason behind DOACs failure in APS is still not consen-
sual. Unlike VKA, they target only one coagulation factor, 
either Xa or IIa,35 and whether directed anticoagulation 
is sufficient or not in patients with APS remains unclear. 
Theoretically, and having in mind the pathophysiology 
of this syndrome, the presence of aPL antibodies consti-
tutes one plausible justification since they can interfere 
with the normal pharmacokinetics of these drugs. Due to 
the fact that aPL antibodies increase lag time and time to 
peak thrombin generation23 and lead to platelet hyper-
activation36 37 and fibrinolysis impairment,38 they might 
be responsible for DOACs’ resistance in APS. Other 
possible drawbacks are suboptimal drug concentration 
demonstrated in animal models,39 as well as the short 
drug half- life that may lead to a fast decline of anticoagu-
lation effect and treatment failure if administrations are 
missed.40
Although meta- analyses on this topic have recently 
been published,35 41–43 our systematic review, in compar-
ison, offers relevant advantages. Our focus was exclu-
sively on patients with APS, without limiting TE events 
to either arterial, venous or microvascular. We included 
RCTs, which are known to better establish the causality 







Anticipated absolute effects (95% CI)
Certainty What happensVKA DOACs Difference
Thromboembolic 
events











DOACs may increase 
the occurrence of 
thromboembolic events 
but the evidence is very 
uncertain.
Major bleeding











DOACs may increase the 
occurrence of major bleeding 
but the evidence is very 
uncertain.
All bleeding events











DOACs may decrease the 
occurrence of all bleeding 
events but the evidence is 
very uncertain.
Mortality











The effect of DOACs on 
mortality is very uncertain.
*Three RCTs classified as having some concerns and three cohort studies at serious risk of bias.
†RR 1.22 (95% CI 0.72 to 2.07).
‡I²=66%.
§Mostly no direct comparison.
¶RR 0.79 (95% CI 0.47 to 1.32).
**RR 1.17 (95% CI 0.48 to 2.84).
††The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI).
DOACs, direct oral anticoagulants; RR, risk ratio; VKA, vitamin K antagonists.
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between drugs and outcomes, and also observational 
studies, whose results provided data on all four existing 
DOACs and less strict APS population. Our pooled data 
also provide objective measure of the DOACs risk in APS 
as results achieved statistical significance concerning TE 
events, supporting some expert consensus.
There are some limitations regarding our review that 
should be taken into account. First, not all included 
studies were clear about using or not the revised Sapporo 
criteria1 in diagnosing APS. To overcome this limitation, 
we performed a subgroup analysis that did not show 
differences between studies with more or less restringing 
inclusion criteria. Second, approximately 67% of our 
population was on rivaroxaban, which could bias our 
conclusions. Indeed, in the subgroup analysis, in studies 
with heterogeneous use of DOACs the significant effect 
of TE events was lost. Third, the grade of certainty of our 
results is very low, due to methodological issues of the 
studies analysed. However, the inclusion of observational 
studies is important and offers some relevant advantages, 
such as a more diversified DOACs samples and the use of 
well- defined inclusion criteria, contributing for a more 
homogeneous population.
This is the best evidence available and until more 
robust evidence is published, physicians need to choose 
which drug benefits the most their patients based on this 
reality.
Currently, two more RCTs are ongoing: ASTRO- APS 
(apixaban for secondary prevention of TE among patients 
with APS) and RISAPS (rivaroxaban for patients who had 
stroke with APS, with or without SLE, follows the results 
of RAPS trial,23 with estimated completion dates for 2021 
and 2023, respectively. The ASTRO- APS will include only 
a strict set of patients with APS with history of venous 
TE. In this study, patients with previous arterial throm-
bosis were excluded as these events may be a marker of 
higher thrombogenicity, recurrent events and potential 
DOACs treatment non- response.35 The RISAPS trial aims 
to study higher intensity anticoagulation with rivarox-
aban (15 mg, two times a day, a dose recommended for 
the acute treatment of VTE) and warfarin (target INR 
3.5)—these being the novelties of this study.
Notwithstanding our data, the ongoing trials, despite 
the existing differences in the population (stricter in 
ATRO- APS), will inform more robustly about the possible 
class effect of DOACs in APS. The need of further trials 
depends on these results.
In conclusion, our review suggests that DOACs use, 
particularly rivaroxaban, among patients with APS, 
appears to be less effective than VKA, since it is associated 
with increased risk of thromboembolic events. In fact, 
some authors44 45 report patients, mostly triple- positive, 
who experienced catastrophic APS—microthromboses 
involving at least three organs within a week46—after 
rivaroxaban introduction. Despite our results advising 
against DOACs, particularly rivaroxaban, judgements 
concerning other DOACs should be more watchful 
considering the ongoing trials, namely ASTRO- APS, that 
might provide additional data on this regard and conse-
quently change the present approach to this class of 
drugs in patients with APS.
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